Loading clinical trials...
Loading clinical trials...
IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy
Conditions
Interventions
Preserved Bimatoprost 0.01%
Tafluprost Unit Dose Preservative Free 15microgram/ml
Locations
7
Austria
Hommer Ophthalmology Institute
Vienna, Austria
UZ Leuven
Leuven, Vlaams Brabant, Belgium
San Paolo Hospital
Milan, Italy
Bietti Foundation
Rome, Italy
Clinical Research Centre Momorial A. de Rotschild
Geneva, Switzerland
Gloucestershire Hospitals NHS Foundation Trust
Gloucestershire, United Kingdom
Start Date
September 1, 2015
Primary Completion Date
May 1, 2017
Completion Date
December 1, 2017
Last Updated
May 12, 2016
NCT04354545
NCT07298356
NCT07396441
NCT06979752
NCT07390890
NCT07145073
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions